ASCO 2020 Prostate Cancer - Results from #60

Viewing 61-71 of 71 articles

ASCO 2020: Safety and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223 Plus Subsequent Taxane Therapy

ASCO 2020: Promising Therapeutic Targets in Prostate Cancer

ASCO 2020: Efficacy and Safety in Older Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone or Enzalutamide in the CARD Study

ASCO 2020: Accuracy of 68Ga-PSMA-11 for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

ASCO 2020: TALAPRO-1: Phase II Study of Talazoparib in Patients with DNA Damage Repair Alterations and mCRPC – Updated interim analysis

ASCO 2020: CONDOR, The Impact of PSMA-targeted Imaging with 18F-DCFPyL-PET/CT on Clinical Management of Patients with Biochemically Recurrent Prostate Cancer

ASCO 2020: TheraP: A Randomised Phase II Trial of 177Lu-PSMA-617 Theranostic Versus Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Progressing after Docetaxel: Initial Results (ANZUP protocol 1603)

ASCO 2020: Health-Related Quality of Life for Olaparib versus Enzalutamide or Abiraterone in mCRPC with Homologous Recombination Repair Gene Alterations: PROfound

ASCO 2020: Phase 3 PROSPER Trial Results: Enzalutamide Demonstrates Significant Improvement in OS in Patients with nmCRPC

ASCO 2020: Darolutamide Demonstrates Significant Improvement in Overall Survival in nmCRPC -The ARAMIS Trial

ASCO 2020: HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist, versus Leuprolide Acetate for Advanced Prostate Cancer

1
2
3
4